Information Provided By: 
Fly News Breaks for December 30, 2016
INNL, PCRX
Dec 30, 2016 | 07:21 EDT
After the FDA refused to accept a new drug application from Innocoll (INNL) for its Xaracoll drug, Janney analyst Ken Trbovich says that Xaracoll was "the most significant near-term threat to Pacira's Exparel franchise." The analyst says that Xaracoll no longer poses a near-term threat to Exparel. He raised his price target on Pacira to $34 from $31 and keeps a Neutral rating on the stock.
News For PCRX;INNL From the Last 2 Days
There are no results for your query PCRX;INNL
